Researchers Have Developed New Cytokine Biosensor
The BIOACT platform enables real-time cytokine profiling in whole blood for point-of-care disease diagnostics.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Should development of point-of-care diagnostics prioritize ease of use in low-resource settings?
Researchers have developed BIOACT, an electrochemical biosensor platform designed to quantify IL-10 and TNF-α cytokines directly in whole blood. The system is currently in the research stage and utilizes a unified calibration model to achieve accuracy levels comparable to plasma testing.
Why it matters
This technology aims to resolve performance limitations in point-of-care diagnostics by enabling cytokine profiling to distinguish between latent and active tuberculosis. It offers a path to faster clinical decision-making in resource-limited settings where standard lab facilities are unavailable.
The BIOACT platform uses an electrochemical biosensor that applies a single calibration model to both whole blood and plasma. This mechanism allows the device to compensate for matrix effects—interference caused by the chemical composition of biological samples—to maintain high accuracy.
The players
BIOACT
An electrochemical biosensor platform developed for multiplexed cytokine detection in whole blood and plasma.
The details
The platform functions as an electrochemical biosensor, a device that converts biological reactions into measurable electrical signals. By employing a specialized calibration model, the system compensates for matrix effects in whole blood, which are the biological background noises that typically complicate point-of-care analysis. This allows the system to achieve diagnostic accuracy previously limited to laboratory plasma testing.
Timeline
October 5, 2026: The research results were published.
The Tech Race
The development of BIOACT follows a trend in point-of-care diagnostic research programs focused on bringing laboratory-grade accuracy to whole-blood clinical testing. This system marks a shift from centralized, plasma-based laboratory workflows toward portable, multi-analyte diagnostics.
The platform is designed to eventually integrate with portable electronics, which would allow clinicians to perform cytokine profiling at the point of care rather than in a centralized lab. It is not currently available for commercial or clinical use.
The takeaway
The research establishes a new baseline for cytokine detection accuracy in whole blood using portable electrochemical sensors. Observers should track the platform's progress toward integrating with portable hardware for clinical use in resource-limited settings.
Further reading
For more information on diagnostic advancements, visit the Biotech section.
More information
View the original peer-reviewed research article for full methodology.
Source note: This article includes information reported by Nature.
Live Poll
Should development of point-of-care diagnostics prioritize ease of use in low-resource settings?
